Targets › SMOC2
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout May 2027.
Promotes matrix assembly and cell adhesiveness (By similarity). Can stimulate endothelial cell proliferation, migration, as well as angiogenesis. (UniProt, Q9H3U7)
Open in Phaseline: the race on SMOC2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mediar Therapeutics | MTX-439 Anti-SMOC2 monoclonal antibody | SMOC2 | Phase 1 | Healthy Adult Participants | May 2027 |
Healthy Adult Participants (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.